Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

Opinion
Video

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Related Content
Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.

Atezolizumab Combo Results Shows Promising Option in EGFR-Mutated NSCLC

Roman Fabbricatore
January 4th 2025
Article

Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC

FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC

ONCOLOGY Staff
January 2nd 2025
Article

The discussion on NSCLC narrowed in on findings out of recent clinical trials, particularly involving a combination regimen of osimertinib and chemotherapy.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

ONCOLOGY Staff
December 28th 2024
Article

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.

Identifying HER2 Mutations for T-DXd Use in NSCLC

Identifying HER2 Mutations for T-DXd Use in NSCLC

ONCOLOGY Staff
December 27th 2024
Article

The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.